• bone;
  • fat;
  • leptin;
  • obesity;
  • osteoporosis


  1. Top of page
  2. Abstract

Recently, leptin has emerged as a potential candidate responsible for protective effects of fat on bone tissue. However, it remains difficult to draw a clear picture of leptin effects on bone metabolism because published data are sometimes conflicting or apparently contradictory. Beyond differences in models or experimental procedures, it is tempting to hypothesize that leptin exerts dual effects depending on bone tissue, skeletal maturity, and/or signaling pathway. Early in life, leptin could stimulate bone growth and bone size through direct angiogenic and osteogenic effects on stromal precursor cells. Later, it may decrease bone remodeling in the mature skeleton, when trabecular bone turnover is high, by stimulating osteoprotegerin (OPG) expression. Leptin negative effects on bone formation effected through central nervous system pathway could counterbalance these peripheral and positive effects, the latter being predominant when the blood-brain barrier permeability decreases or the serum leptin level rises above a certain threshold. Thus, the sex-dependent specificity of the relationship between leptin and bone mineral density (BMD) in human studies could be, at least in part, caused by serum leptin levels that are two- to threefold higher in women than in men, independent of adiposity. Although these hypotheses remain highly speculative and require further investigations, existing studies consistently support the role of leptin as a link between fat and bone.


  1. Top of page
  2. Abstract

Although obesity is a major risk factor for many diseases and has become a severe burden on healthcare costs in Western societies, it may have at least one beneficial effect, that of preventing osteoporosis, itself another major health problem. Indeed, it is well established that body weight is one of the strongest predictors of bone mass in both sexes.(1–5) However, the mechanisms that explain this relationship remain unclear and there is still ongoing controversy as to whether body fat mass (BFM) or lean mass is a better predictor of bone mineral density (BMD).(5–9)

The relationship between fat mass and bone mass also appears to be gender specific. Reid et al.(10) found no association in men, but they and others(9–11) did find a significant relationship between BFM and BMD in women. Early after menopause, a higher body mass index (BMI) is related to a slower bone loss rate induced by estrogen deficiency.(12,13) In a group of elderly female hip fracture patients, BFM has been shown to be a better explanatory factor for hip fracture than lean mass or body weight.(14) Likewise, in the prospective cohort study EPIDOS, a decrease of 1 SD in BFM was associated with a 30% increase in hip fracture risk, whereas lean mass was not significantly associated with fracture risk.(15)

Obesity-induced mechanical loading certainly is a contributing factor in the positive relationship between BFM and BMD. But this protective effect has been observed even at non-weight-bearing bone sites.(11) Thus, factors other than skeletal loading are likely important in mediating the relationship between BFM and BMD. Indeed, several lines of evidence have suggested that the effects of BFM on BMD may be mediated by hormonal factors, including estrogens and insulin. Adipose tissue produces estrogens by aromatization of androgens,(16) which represents the principal source of estrogens after menopause.(17) This peripheral estrogen production could affect bone turnover and BMD, especially after menopause.(18,19) However, BFM and BMD remain positively and strongly correlated in women, even after adjusting for serum estrogen levels.(20,21) It remains controversial as to whether BFM is better associated with BMD before(22,23) or after menopause.(6,24)

Serum insulin levels also have been shown to be related to BMD,(25) and hyperinsulinemia has been proposed as a potential explanation for the association between obesity and BMD in women, perhaps because of direct mitogenic effects of insulin on osteoblasts.(26,27) However, patients with non-insulin-dependent diabetes mellitus have been reported to have increased, decreased, or unchanged BMD (reviewed by Thomas et al.(28)). Hence, other humoral or metabolic factors are almost certainly involved in the mechanisms of fat-induced bone protection.

Recently, leptin has emerged as a potential candidate responsible for protective effects of fat on bone tissue. Leptin, the product of the ob gene, is secreted mainly by white adipose tissue(29) and is correlated strongly with BFM.(30–32) This 14-kDa protein is a representative marker of the body's energetic status and raises considerable interest. In fact, in addition to its effects on the central nervous system,(33,34) recent studies provide new evidence of its role in many different metabolic pathways. Besides insulin action, to which leptin is related strongly, leptin may alter numerous endocrine functions, for example, hormonal secretion from the anterior pituitary,(35) ovaries,(36) testes,(37) thyroid, and adrenal glands.(38) Experimental data suggest that the central loop of leptin action regulating appetite and these peripheral effects on endocrine glands are not related.(39) In addition to these effects, leptin may act as a growth factor, with the ability of directly enhancing development of hemopoietic precursor cells,(40–44) myoblast-like cells,(45,46) or lung cells.(47) Furthermore, it can modulate jejunum epithelial cell activity,(48) and even more importantly, it exerts angiogenic effects on vascular endothelial cells.(49) Conversely, leptin suppresses specific biochemical reactions that contribute to adipocyte differentiation and lipid accumulation.(50,51) Leptin acts through highly specific receptors,(52) which have been described on hemopoietic precursor cells,(40) in placenta and several fetal tissues,(53) white and brown adipocytes,(54) in lung tissue,(49) and the jejunum.(47)

Are bone cells potential targets for leptin?

Bone marrow stromal cells have the ability of differentiating into osteoblasts as well as adipocytes, chondroblasts, and myoblasts.(55) Thomas et al.,(56) using a human stromal cell line, and others(57–60) showed that these cells might respond to leptin action because they expressed both short and long forms of leptin receptors. This expression might be dependent on the differentiation stage, because Ducy et al.(61) found no expression of these receptors in mature murine osteoblasts. Both leptin and its receptors also were found in murine fetal cartilage/bone template(62) as well as in the growth plate, especially in chondrocytes close to the vascular invasion of this tissue.(63) These data are of great interest regarding the recently shown angiogenic properties of leptin.(49)

Do we have evidence that leptin affects bone metabolism?

First, several in vitro studies suggest that stromal cells respond to leptin stimulation. Takahashi et al.(64) showed that leptin induced MAPK-dependent cell proliferation in the mouse embryonic cell line C3H10T1/2, a multipotential stromal cell line. These data recently were confirmed on a different osteoblastic cell line.(58) These effects could be differentiation stage-dependent, because Thomas et al.(56) observed no effect on proliferation in the human marrow stromal cell line hMS2-12, progenitor cells that probably are more mature than the C3H10T1/2 cells. Conversely, leptin administration increased osteoblastic differentiation of these hMS2-12 cells, leading to an increase in the mineralization of the extracellular matrix.(56) Similar results were observed in other cell models, with an increased number of mineralized nodules in rat cell culture treated with leptin(65) and in long-term human osteoblast cultures.(60)

Leptin could be one of several factors that modulate the reciprocal differentiation of stromal cells between osteoblastic and adipocytic pathways, because it has the ability to inhibit adipogenesis in a negative feedback loop.(50,56) The cellular mechanisms, which mediate these effects, remain unclear. The leptin-induced activation of the MAPK cascade may be critical because these biochemical events stimulate both osteoblastic differentiation(66) and phosphorylation of peroxisome proliferator-activated receptor (PPARγ), which has been shown to inhibit adipogenesis.(67)

In addition to direct positive effects on the osteoblastic differentiation of stromal cells, leptin also may modulate bone remodeling. Indeed, it has been shown recently in human stromal cells that leptin inhibited the expression of RANKL, the major downstream cytokine controlling osteoclastogenesis.(68) Furthermore, it stimulated the expression of osteoprotegerin (OPG), its decoy receptor, by stromal cells(68) or mononuclear cells.(69) Leptin also was able to induce the expression and secretion of the interleukin (IL)-1 receptor antagonist by human monocytes,(70) which could blunt an IL-1-related increase in bone turnover, another key event in estrogen deficiency-induced bone loss.

Although leptin may exert direct effects on preosteoblastic stromal cells, one has to keep in mind that its effects on different endocrine systems could indirectly alter bone metabolism as well. In fact, leptin has been shown to modulate the growth hormone /insulin-like growth factor pathway,(71) the pituitary-thyroid axis,(72) as well as the pituitary-adrenal,(38) and gonadal axis.(36) The relative contribution of these effects to the resultant action of leptin on bone remains largely undetermined.

Second, animal studies strongly suggest that leptin alters bone metabolism, but conclusions on the nature of these effects remain highly controversial so far. Logically, several studies have explored the putative effects of leptin on bone metabolism using animals either deficient in leptin, that is, the ob/ob mice, or with mutation in the leptin-receptor, that is, the fa/fa Zucker rats and the db/db mice. Foldes et al.(73) showed that the obese fa/fa rats had a lower bone mass with shorter and lighter femurs, as compared with their normal littermates (NLMs). The decrease in bone mass was associated with an increase in bone resorption activity. Trabecular microarchitecture was also altered with an increase in trabecular number but a decrease in trabecular thickness and no change in trabecular bone volume. A recent report on fa/fa rats presented different data with a significant increase in trabecular bone volume resulting in a significant increase in biomechanical strength of long bones.(74) The reasons for these discrepancies remain unclear but the association of thicker cortices and shorter bones indeed may explain an improved mechanical strength.

Two studies evaluating the effects of peripheral leptin administration in ob/ob mice observed a stimulatory effect on bone growth(59) with a dramatic increase in cortical bone formation(75) in treated animals as compared with their controls. Indeed, intraperitoneal leptin administration to 4-week-old ob/ob male mice for 3 weeks reversed the defect in bone growth and osteopenia, as measured by DXA and peripheral quantitative computerized tomography (pQCT), despite a 40% decrease in food intake and a 14% decrease in body weight.(59) No effect was observed in the lean littermates.

In contrast, Ducy et al. reported that 3-month and 6-month old ob/ob mice and db/db mice had higher bone mass associated with a higher mineral apposition rate as compared with their wild-type littermates, despite hypogonadism and hypercortisolism secondary to leptin deficiency.(61) Furthermore, they showed that intracerebroventricular (icv) administration of leptin to 4-month old ob/ob female mice for 4 weeks normalized their bone mass. Therefore, these authors suggested that the increase in BMD observed in obese humans might be secondary to leptin resistance, a phenomenon believed to be critical in human obesity development.(76) This leptin resistance has been related first to a defect of leptin transport across the blood-brain barrier(77) into the central nervous system, as suggested by a more efficient leptin uptake (measured as the cerebro-spinal fluid [CSF]/plasma leptin ratio) up to four to six times greater in lean compared with obese individuals.(78–80) Second, a true hypothalamic resistance to leptin might occur with the onset of obesity, because there was no correlation between cerebrospinal fluid concentrations of leptin and its principal mediators neuropeptide Y (NPY) and melanocyte stimulating hormone (α-MSH) in obese women.(81) Furthermore, a progressive resistance to icv administration of leptin on food intake accompanied the development of high fat diet-induced obesity in C57Bl/6J mice.(82,83)

The reasons for discrepancies between different studies using the ob/ob mice model remain unclear. Age or sex might play a role but similar data were observed in male mice.(61) Actually, the most striking difference was the route of leptin administration. Ducy et al. reported no change in serum leptin levels after icv leptin infusion,(61) strongly suggesting a central regulation of bone metabolism through a cascade of neuroendocrine events triggered by leptin. Paradoxically, these authors observed the same effects in inhibiting bone formation with icv administration of the neuropeptide Y,(61) an orexigenic peptide negatively regulated by leptin at the hypothalamus level in the satiety control loop.(84) Recently, Baldock et al.(85) reported interesting but puzzling data confirming, first, the existence of a central nervous regulation of bone formation and, second, the negative effects of NPY on osteoblast activity. Indeed, they showed that mice deficient in Y2 receptors (one of the five NPY receptor types) had a twofold increase in trabecular bone volume. Furthermore, they showed that a selective deletion of hypothalamic Y2 receptors induced a similar increase in bone mass with a stimulated osteoblast activity and no change in osteoclast surfaces.

Next, recent studies, using normal rodent animals, indeed support the hypothesis that leptin effects on bone could depend on the site of administration and, therefore, the signaling pathway activated. Burguera et al.(68) showed that continuous subcutaneous administration of leptin to 6-month-old rats was able to prevent partially the rapid bone loss induced by estrogen deficiency, in accordance with leptin in vitro effects on OPG expression and osteoclastogenesis.(68,69) Using another model of rapid bone loss, the tail-suspended rat, characterized by a rapid increase in bone resorption and a sustained decrease in bone formation, Thomas et al.(86) recently showed that a similar administration of leptin prevented disuse-induced bone loss. In addition, systemic daily administration of leptin to sexually mature male mice significantly increased bone strength by >20%.(58)

Third, human cross-sectional studies provide data, which, however, are less conclusive. Although some authors(87–89) reported a positive association between serum leptin levels and BMD, others(90–92) failed to find such a relationship. In a large cohort of 692 subjects, Thomas et al.(87) observed a positive association between leptin and BMD in women but not in men, regardless of the bone site (weight-bearing or not) and menopausal status. Furthermore, adjusting for leptin significantly reduced the positive association between BFM and BMD in women. However, because leptin is almost exclusively produced by fat with a very strong association between serum leptin levels and fat mass,(30–32) the relationship between leptin and BMD disappeared after adjusting for fat mass in most(87,88,91) but not all(89) studies. Interestingly, Pasco et al.(93) recently reported a direct relationship between serum leptin level and bone mineral content (BMC) at the femur and lateral spine and with BMD at the lateral spine, even after adjusting for fat mass in a population of 214 healthy nonobese women aged 20–91 years old. These data, together with a previous study showing a positive association between serum leptin level and whole body bone area,(94) suggest that leptin might act on the periosteal envelope of cortical bone, thereby increasing bone size. Moreover, in a group of 139 postmenopausal women aged 48–78 years old, leptin levels were significantly lower in postmenopausal women with vertebral fractures than in those without fracture.(89) In this study, multiple regression analysis showed leptin but not fat mass, as a significant contributing factor to fracture presence.(89)

In addition, there is some evidence that leptin may act as a growth factor during fetal development. Leptin and its receptor are produced by human placenta(95) and umbilical cord leptin levels are associated positively with height(96) and weight(97,98) at birth in humans. This association was independent of insulin-like growth factor I cord levels.(98) Furthermore, leptin levels in umbilical cord blood were independently associated with intrauterine growth after adjusting for adiposity, placental weight, insulin, and maternal leptin levels.(99)

Finally, pathological evidence in humans also provides evidence that leptin could exert direct or indirect effects on bone metabolism. Osteoporosis is a very severe feature of anorexia nervosa (AN), which displays an endocrine profile including hypogonadism and hypercorticism and dramatically reduced serum levels of leptin.(100) The magnitude of bone loss is much higher in AN than in hypothalamic amenorrhea and is related to nutritional factors in addition to the magnitude and duration of estrogen deficiency; estrogen replacement is not sufficient to prevent fully such a bone loss.(101) Interestingly, Karlsson et al.(101) recently suggested in a cross-sectional study in women with AN that estrogen deficiency may reduce volumetric BMD, the true bone density, whereas reduced bone size observed in AN may be more related to nutritional disorders. Likewise, bulimic women with functional amenorrhea and significantly decreased leptin levels had a lower BMD despite normal body weight.(102)

Case-reports in other patient populations include the observation of Shirakura et al.,(103) who documented a significant increase in serum leptin levels in women with ossification of spinal ligaments, as compared with matched controls. Ozata et al.(104) reported, in a highly consanguineous extended pedigree with a missense leptin gene mutation, four homozygous patients exhibiting alterations in parathyroid hormone (PTH)-calcium function; one of them had a low BMD despite significant obesity. Last but not least, Farooqi et al.(105) evaluated the effects of a 1-year recombinant leptin therapy in a 9-year-old girl with congenital leptin deficiency and severe obesity. They observed a 15.6-kg decrease in fat mass and a 0.82-kg decrease in lean mass concurrent with a 0.15-kg increase in whole body BMD.

In summary, it remains difficult to draw a clear picture of leptin effects on bone metabolism, because data appear sometimes conflicting or contradictory. Beyond differences in models or experimental procedures, it is tempting, so far, to hypothesize that leptin exerts dual effects depending on the bone tissue or the signaling pathway. Thus, early in life, leptin could stimulate bone growth and bone size through angiogenic effects and osteogenic activity in immature cortical bone. Later, it may decrease bone remodeling in the mature skeleton when trabecular bone turnover is high. Central negative effects could counterbalance these peripheral and positive effects, the latter being predominant only when central leptin resistance occurs or else when serum leptin level rises above a certain threshold. Therefore, the sex-dependent specificity of the relationship between leptin and BMD in human studies could be at least in part due to serum leptin levels that are 2- to 3-fold higher in women than in men, independent of adiposity. While these hypotheses remain highly speculative and require further investigations, existing studies consistently support the role of leptin as a link between fat and bone.


  1. Top of page
  2. Abstract
  • 1
    Seeman E, Melton LJ, O'Fallon WM, Riggs BL 1983 Risk factors for spinal osteoporosis in men. Am J Med 75:977983.
  • 2
    Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL 1989 Epidemiology of vertebral fractures in women. Am J Epidemiol 129:10001011.
  • 3
    Pocock N, Eisman J, Gwinn T, Sambrook P, Kelly P, Freund J, Yeates M 1989 Muscle strength, physical fitness, and weight but not age predict femoral neck bone mass. J Bone Miner Res 4:441448.
  • 4
    Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC Jr 1990 Predictors of bone mass in perimenopausal women. Ann Intern Med 112:96101.
  • 5
    Felson DT, Zhang Y, Hannan MT, Anderson JJ 1993 Effects of weight, and body mass index on bone mineral density in men and women. J Bone Miner Res 8:567573.
  • 6
    Lindsay R, Cosman F, Herrington BS, Himmelstein S 1992 Bone mass and body composition in normal women. J Bone Miner Res 7:5562.
  • 7
    Edelstein SH, Barrett-Connor E 1993 Relationship between body size and bone mineral density in elderly and women. Am J Epidemiol 138:160169.
  • 8
    Glauber HS, Vollmer WM, Nevitt MC, Ensrud KE, Orwoll ES 1995 Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab 80:11181123.
  • 9
    Khosla S, Atkinson EJ, Riggs BL, Melton LJ 1996 Relationship between body composition and bone mass in women. J Bone Miner Res 11:857863.
  • 10
    Reid IR, Plank LD, Evans MC 1992 Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 75:779782.
  • 11
    Hla MM, Davis JW, Ross PD, Wasnick RD, Yates AJ, Ravn P, Hosking DJ, McClung MR, the Early Postmenopausal Intervention Cohort (EPIC) Study Group 1996 A multicenter study of the influence of fat and lean mass on bone mineral content: Evidence for difference in their relative influence at major fracture sites. Am J Clin Nutr 64:354360.
  • 12
    Tremollieres FA, Pouilles JM, Ribot C 1993 Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 77:683686.
  • 13
    Revilla M, Villa LF, Sánchez-Atrio A, Hernández ER, Rico H 1997 Influence of body mass index on the age-related slope of total and regional bone mineral content. Calcif Tissue Int 61:134138.
  • 14
    Galvard H, Elmstahl S, Elmstahl B, Samuelsson SM, Robertsson E 1996 Differences in body composition between female geriatric hip fracture patients and healthy controls: Body fat is more important as an explanatory factor for the fracture than body weight and lean body mass. Aging Clin Exp Res 8:282286.
  • 15
    Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, Meunier PJ 1998 How hip and whole-body bone mineral density predict hip fracture in elderly women: The EPIDOS Prospective Study. Osteoporos Int 8:247254.
  • 16
    Schindler AE, Ebert A, Friedrich E 1972 Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 35:627630.
  • 17
    Grodin JM, Siiteri PK, MacDonald PC 1973 Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207214.
  • 18
    Heshmati HM, Khosla S, Robins SP, Geller N, McAlister CA, Riggs BL 1997 Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women. J Bone Miner Res 12:S1;S121.
  • 19
    Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:22662274.
  • 20
    Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TMT, Cundy TF 1992 Determinants of total body and regional bone mineral density in normal postmenopausal women. J Clin Endocrinol Metab 75:4551.
  • 21
    Kleerekoper M, Nelson DA, Peterson EL, Wilson PS, Jacobsen G, Longcope C 1994 Body composition and gonadal steroids in older white and black women. J Clin Endocrinol Metab 79:775779.
  • 22
    Aloia JF, Vaswani A, Ma R, Flaster E 1995 To what extent is bone mass determined by fat-free or fat mass? Am J Clin Nutr 61:11101114.
  • 23
    Douchi T, Oki T, Nakamura S, Ijuin H, Yamamoto S, Nagata Y 1997 The effect of body composition on bone density in pre- and postmenopausal women. Maturitas 27:5560.
  • 24
    Martini G, Valenti R, Giovani S, Nuti R 1997 Age-related changes in body composition of healthy and osteoporotic women. Maturitas 27:2533.
  • 25
    Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J 1993 Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol 265:E655—E659.
  • 26
    Hickman J, McElduff A 1989 Insulin promotes growth of the cultured rat osteosarcoma cell line UMR106–01: An osteoblast-like cell. Endocrinology 124:701706.
  • 27
    Barrett-Connor E, Kritz-Silverstein D 1996 Does hyperinsulinemia preserve bone? Diabetes Care 19:13881392.
  • 28
    Thomas DM, Ng KW, Best JD 1997 Insulin and bone: A clinical and scientific review. Endocrinol Metab 4:517.
  • 29
    Cinti S, Frederich RC, Zingaretti MC, Dematteis R, Flier JS, Lowell BB 1997 Immunohistochemical localization of leptin and uncoupling protein in white and brown adipose tissue. Endocrinology 138:797804.
  • 30
    Maffei M, Halaas JL, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM 1995 Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1:11551161.
  • 31
    Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292295.
  • 32
    Thomas T, Burguera B, Melton LJ III, Atkinson EJ, Riggs BL, Khosla S 2000 Relationship of serum leptin levels with body composition, sex steroid, and insulin levels in men and women. Metabolism 49:12781284.
  • 33
    Rosenbaum M, Leibel RL, Hirsch J 1997 Obesity. N Engl J Med 337:396407.
  • 34
    Couce ME, Burguera B, Parisi JE, Jensen MD, Lloyd RV 1997 Localization of the leptin receptor in the human brain. Neuroendocrinology 66:145150.
  • 35
    Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM 1997 Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 94:10231028.
  • 36
    Spicer LJ, Francisco CC 1997 The adipose obese gene product, leptin: Evidence of a direct inhibitory role in ovarian function. Endocrinology 138:33743379.
  • 37
    Caprio M, Isidori AM, Carta AR, Moretti C, Dufau ML, Fabbri A 1999 Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 140:493947.
  • 38
    Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, Scherbaum WA 1997 Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: Leptin inhibits cortisol release directly. Diabetes 46:12351238.
  • 39
    Henry BA, Goding JW, Alexander WS, Tilbrook AJ, Canny BJ, Dunshea F, Rao A, Mansell A, Clarke IJ 1999 Central administration of leptin to ovariectomized ewes inhibits food intake without affecting the secretion of hormones from the pituitary gland: Evidence for a dissociation of effects on appetite and neuroendocrine function. Endocrinology 140:11751182.
  • 40
    Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W 1996 A role for leptin and its cognate receptor in hematopoiesis. Curr Biol 6:11701180.
  • 41
    Cioffi JA, Shafer AW, Zupancic TJ, Smith-Gbur J, Mikhail A, Platika D, Snodgrass HR 1996 Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction. Nat Med 2:585589.
  • 42
    Gainsford T, Willson TA, Metcalf D, Handman E, Mcfarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ 1996 Leptin can induce proliferation, differentiation, and functional activation of hemopoeitic cells. Proc Natl Acad Sci USA 93:1456414568.
  • 43
    Mikhail AA, Beck EX, Shafer A, Barut B, Gbur JS, Zupancic TJ, Schweitzer AC, Cioffi JA, Lacaud G, Ouyang B, Keller G, Snodgrass HR 1997 Leptin stimulates fetal and adult erythroid and myeloid development. Blood 89:15071512.
  • 44
    Umemoto Y, Tsuji K, Yang FC, Ebihara Y, Kaneko A, Furukawa S, Nakahata T 1997 Leptin stimulates the proliferation of murine myelocytic and primitive hematopoeitic progenitor cells. Blood 90:34383443.
  • 45
    Liu YL, Emilsson V, Cawthorne MA 1997 Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob/ob) mice. FEBS Lett 411:351355.
  • 46
    Kellerer M, Koch M, Metzinger E, Mushack J, Capp E, Häring HU 1997 Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. Diabetologia 40:13581362.
  • 47
    Tsuchiya T, Shimizu H, Horie T, Mori M 1999 Expression of leptin receptor in lung: Leptin as a growth factor. Eur J Pharmacol 365:273279.
  • 48
    Morton NM, Emilsson V, Liu YL, Cawthorne MA 1998 Leptin action in intestinal cells. J Biol Chem 273:2619426201.
  • 49
    Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR 1998 Biological action of leptin as an angiogenic factor. Science 281:16831686.
  • 50
    Bai Y, Zhang S, Kim KS, Lee JK, Kim KH 1996 Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. J Biol Chem 271:1393913942.
  • 51
    Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, Unger RH 1997 Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 94:46374641.
  • 52
    Flier JS 1997 Leptin expression and action: New experimental paradigms. Proc Natl Acad Sci USA 94:42424245.
  • 53
    Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P, Mercer JG 1997 Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci USA 94:1107311078.
  • 54
    Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, Boss O, Pernin A, Chin WW, Cusin I, Rohner-Jeanrenaud F, Burger AG, Zapf J, Meier CA 1997 Direct effects of leptin on brown and white adipose tissue. J Clin Invest 100:28582864.
  • 55
    Owen M 1985 Lineage of osteogenic cells and their relationship to the stromal system. In: PeckWA (ed.) Bone and Mineral Research, vol 3. Elsevier, Amsterdam, The Netherlands, pp. 123.
  • 56
    Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL 1999 Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:16301638.
  • 57
    Bassilana F, Susa M, Keller HJ, Halleux C 2000 Human mesenchymal stem cells undergoing osteogenic differentiation express leptin and functional leptin receptor. J Bone Miner Res 15:S1;S378.
  • 58
    Cornish J, Callon KE, Bava U, Lin QX, Naot D, Hill BL, Broom ND, Reid ID 2001 The direct acions of leptin on bone cells increase bone strength in vivo -an explanation of low fracture rates in obesity. Bone 28(Suppl):S88.
  • 59
    Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG 2000 Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92:7378.
  • 60
    Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Gordeladze JO, Drevon CA 2001 Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 16:14261433.
  • 61
    Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen JH, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197207.
  • 62
    Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P, Mercer JG 1997 Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci USA 94:1107311078.
  • 63
    Kume K, Satomura K, Nishisho S, Kitaoka E, Yamanouchi K, Tobiume S, Nagayama M 2002 Potential role of leptin in endochondral ossification. J Histochem Cytochem 50:159169.
  • 64
    Takahashi Y, Okimura Y, Mizuno I, Iida K, Takahashi T, Kaji H, Abe H, Chihara K 1997 Leptin induces mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells. J Biol Chem 272:1289712900.
  • 65
    Iwaniec UT, Shearon CC, Heaney RP, Cullen DM, Yee JA 1998 Leptin increases number of mineralized bone nodules in vitro. Bone 23(Suppl):S212.
  • 66
    Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL 2001 Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 276:1444314450.
  • 67
    Hu E, Kim JB, Sarraf P, Spiegelman BM 1996 Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274:21002103.
  • 68
    Burguera B, Hofbauer L, Thomas T, Gori F, Lassam J, Laasko K, Evans G, Khosla S, Riggs BL, Turner RT 2001 Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142:35463553.
  • 69
    Holloway WR, Collier FM, Aitken CJ, Malakellis M, Gough TJ, Myers DE, Collier GR, Nicholson GC 2000 Leptin inhibits osteoclast generation. J Bone Miner Res 15:S1;S174.
  • 70
    Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA 2001 Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J Clin Endocrinol Metab 86:783789.
  • 71
    Gregoire Nyomba BL, Johnson M, Berard L, Murphy LJ 1999 Relationship between serum leptin and the insulin-like growth factor-I system in humans. Metabolism 48:840844.
  • 72
    Flier JS, Harris M, Hollenberg AN 2000 Leptin, nutrition, and the thyroid: The why, the wherefore, and the wiring J Clin Invest 105:859861.
  • 73
    Foldes J, Shih MS, Levy J 1992 Bone structure and calcium metabolism in obese Zucker rats. Int J Obes 16:95102.
  • 74
    Holzmann T, Schilling AF, Beil T, Rueger JM, Karsenty G, Amling M 2000 Central control of bone mass by leptin in rats. J Bone Miner Res 15:S1;S471.
  • 75
    Liu C, Grossman A, Bain S, Strachan M, Puerner D, Bailey C, Humes J, Lenox J, Yamamoto G, Sprugel K, Kuiper J, Weigle S, Durman D, Moore E 1997 J Bone Miner Res 12:S1;S115.
  • 76
    Spiegelman BM, Flier JS 2001 Obesity and the regulation of energy balance. Cell 104:531543.
  • 77
    Burguera B, Curran G, Couce ME, Lamsam J, Cleary M, Poduslo J 2000 Obesity is associated with a decreased of leptin transport across the blood brain barrier and up regulation of leptin receptor in the hypothalamus. Diabetes 49:12191223.
  • 78
    Couce ME, Green D, Brunetto A, Achim C, Lloyd RV, Burguera B 2001 Limited brain access for leptin in obesity. Pituitary 4:101110.
  • 79
    Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV 1996 Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 348:159161.
  • 80
    Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D 1996 Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans. Nat Med 2:589593.
  • 81
    Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, Marcus C 2001 Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J Clin Endocrinol Metab 86:48494853.
  • 82
    El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS 2000 Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 105:18271832.
  • 83
    Lin S, Thomas TC, Storlien LH, Huang XF 2000 Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24:639646.
  • 84
    Casanueva FF, Dieguez C 1999 Neuroendocrine regulation and actions of leptin. Front Neuroendocrinol 20:317363.
  • 85
    Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H 2002 Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915921.
  • 86
    Thomas T, de Vittoris R, David VN, Vico L, Lafage-Proust MH, Alexandre C 2001 Leptin prevents disuse-induced bone loss in tail-suspended female rats. J Bone Miner Res 16:S1;S143.
  • 87
    Thomas T, Burguera B, Melton LJ III, Atkinson EJ, Riggs BL, Khosla S 2001 Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114120.
  • 88
    Goulding A, Taylor RW 1998 Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in post-menopausal women. Calcif Tissue Int 63:456458.
  • 89
    Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K 2001 Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 55:341347.
  • 90
    Rauch F, Blum WF, Klein K, Allolio B, Schonau E 1998 Does leptin have an effect on bone in adult women? Calcif Tissue Int 63:453455.
  • 91
    Odabasi E, Ozata M, Turan M, Bingol N, Yonem A, Cakir B, Kutlu M, Ozdemir IC 2000 Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol 142:170173.
  • 92
    Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R 2001 Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 28:1137.
  • 93
    Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC 2001 Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86:18841887.
  • 94
    Matkovic V, Ilich JZ, Skugor M, Badenhop NE, Goel P, Clairmont A, Klisovic D, Nahhas RHW, Landoll JD 1997 Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 82:32393245.
  • 95
    Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, Nakao K 1997 Nonadipose tissue production of leptin. Leptin as a novel placenta-derived hormone in humans. Nat Med 3:10291033.
  • 96
    Boguszewski M, Dahlgren J, Bjarnason R, Rosberg S, Carlsson LMS, Albertssonwikland K 1997 Serum leptin in short children born small for gestational age. Relationship with the growth response to growth hormone treatment. Eur J Endocrinol 137:387395.
  • 97
    Harigaya A, Nagashima K, Nako Y, Morikawa A 1997 Relationship between concentration of serum leptin and fetal growth. J Clin Endocrinol Metab 82:32813284.
  • 98
    Christou H, Connors JM, Ziotopoulou M, Hatzidakis V, Papathanassoglou E, Ringer SA, Mantzoros CS 2001 Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth. J Clin Endocrinol Metab 86:935938.
  • 99
    Varvarigou A, Mantzoros CS, Beratis NG 1999 Cord blood leptin concentrations in relation to intrauterine growth. Clin Endocrinol (Oxf) 50:177183.
  • 100
    Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, Herzog D, Klibanski A 1999 Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 84:20492055.
  • 101
    Karlsson MK, Weigall SJ, Duan Y, Seeman E 2000 Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. J Clin Endocrinol Metab 85:31773182.
  • 102
    Warren MP, Voussoughian F, Geer EB, Hyle EP, Adberg CL, Ramos RH 1999 Functional hypothalamic amenorrhea: Hypoleptinemia and disordered eating. J Clin Endocrinol Metab 84:8737.
  • 103
    Shirakura Y, Sugiyama T, Tanaka H, Taguchi T, Kawai S 2000 Hyperleptinemia in female patients with ossification of spinal ligaments. Biochem Biophys Res Commun 267:752755.
  • 104
    Ozata M, Ozdemir IC, Licinio J 1999 Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84:36863695.
  • 105
    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S 1999 Brief Report: Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency. N Engl J Med 341:879884.